Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan succinate, quantity: 70 mg (equivalent: sumatriptan, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; lactose; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - imigran tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran tablets in the treatment of basilar or hemiplegic migraines.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan succinate, quantity: 140 mg (equivalent: sumatriptan, qty 100 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose - sumatriptan (imigran) tablets and injection are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hyprolose; sodium starch glycollate type a; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; maize starch; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; hyprolose; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: citric acid; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; mannitol; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; mannitol; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; citric acid; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; citric acid; pregelatinised maize starch; mannitol; povidone; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; povidone; pregelatinised maize starch; mannitol; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).